Study of CT-01 for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called CT-01, either alone or with another drug, for people with intermediate or advanced liver cancer (hepatocellular carcinoma) that has worsened after standard treatments. It might help if you have not responded to or could not tolerate previous therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with liver cancer that cannot be cured with surgery.
- Your cancer is at an intermediate or advanced stage and has gotten worse despite at least one prior treatment.
- You have at least one tumor in your liver that can be measured on a scan.
- Your liver function is good (Child-Pugh class A, score 5-6) and you are in generally good health (ECOG score 0 or 1).
- You do not have a history of liver transplant, active brain tumors, or serious bleeding in your stomach or esophagus in the last month.
- You are willing to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests a new drug called TPST-1120 combined with two standard treatments (atezolizumab and bevacizumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination works better than the standard approach alone.
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
This trial studies how well a combination of chemotherapy, immunotherapy, and an anti-angiogenesis medicine works for advanced hepatocellular carcinoma (HCC), a type of liver cancer. It may help slow tumor growth and improve outcomes by attacking cancer in different ways.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.